Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Oct 14:9:1026083.
doi: 10.3389/fmed.2022.1026083. eCollection 2022.

Immuno-PET: Design options and clinical proof-of-concept

Alexandre Lugat  1 , Clément Bailly  1   2 , Michel Chérel  1   3 , Caroline Rousseau  1   3 , Françoise Kraeber-Bodéré  1   2 , Caroline Bodet-Milin  1   2 , Mickaël Bourgeois  1   2   4
Affiliations
Review

Immuno-PET: Design options and clinical proof-of-concept

Alexandre Lugat et al. Front Med (Lausanne). .

Abstract

Radioimmunoconjugates have been used for over 30 years in nuclear medicine applications. In the last few years, advances in cancer biology knowledge have led to the identification of new molecular targets specific to certain patient subgroups. The use of these targets in targeted therapies approaches has allowed the developments of specifically tailored therapeutics for patients. As consequence of the PET-imaging progresses, nuclear medicine has developed powerful imaging tools, based on monoclonal antibodies, to in vivo characterization of these tumor biomarkers. This imaging modality known as immuno-positron emission tomography (immuno-PET) is currently in fastest-growing and its medical value lies in its ability to give a non-invasive method to assess the in vivo target expression and distribution and provide key-information on the tumor targeting. Currently, immuno-PET presents promising probes for different nuclear medicine topics as staging/stratification tool, theranostic approaches or predictive/prognostic biomarkers. To develop a radiopharmaceutical drug that can be used in immuno-PET approach, it is necessary to find the best compromise between the isotope choice and the immunologic structure (full monoclonal antibody or derivatives). Through some clinical applications, this paper review aims to discuss the most important aspects of the isotope choice and the usable proteic structure that can be used to meet the clinical needs.

Keywords: diagnosis; immuno-PET; monoclonal antibody; nuclear medicine; theranostic.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. Strebhardt K, Ullrich A, Strebhardt K, Ullrich A. Paul Ehrlich's magic bullet concept: 100 years of progress. Nat Rev Cancer. (2008) 8:473-80. 10.1038/nrc2394 - DOI - PubMed
    1. Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. (1975) 256:495-7. 10.1038/256495a0 - DOI - PubMed
    1. Goldenberg DM, DeLand F, Kim E, Bennett S, Primus FJ, van Nagell JR, et al. . Use of radiolabeled antibodies to carcinoembryonic antigen for the detection and localization of diverse cancers by external photoscanning. N Engl J Med. (1978) 298:1384-6. 10.1056/NEJM197806222982503 - DOI - PubMed
    1. Herlyn M, Steplewski Z, Herlyn D, Koprowski H. Colorectal carcinoma-specific antigen: detection by means of monoclonal antibodies. Proc Natl Acad Sci USA. (1979) 76:1438-42. 10.1073/pnas.76.3.1438 - DOI - PMC - PubMed
    1. DeNardo SJ, DeNardo GL, O'Grady LF, Macey DJ, Mills SL, Epstein AL, et al. . Treatment of a patient with B cell lymphoma by I-131 LYM-1 monoclonal antibodies. Int J Biol Markers. (1987) 2:49-53. 10.1177/172460088700200107 - DOI - PubMed